F
Fabio M. Iwamoto
Researcher at Columbia University
Publications - 153
Citations - 6630
Fabio M. Iwamoto is an academic researcher from Columbia University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 126 publications receiving 5329 citations. Previous affiliations of Fabio M. Iwamoto include University of Texas MD Anderson Cancer Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Junfei Zhao,Andrew X. Chen,Robyn D. Gartrell,Andrew M. Silverman,Luis Aparicio,Tim Chu,Darius Bordbar,David Shan,Jorge Samanamud,Aayushi Mahajan,Ioan Filip,Rose Orenbuch,Morgan Goetz,Jonathan T. Yamaguchi,Michael Cloney,Craig Horbinski,Rimas V. Lukas,Jeffrey Raizer,Ali I Rae,Jinzhou Yuan,Peter Canoll,Jeffrey N. Bruce,Yvonne M. Saenger,Peter A. Sims,Fabio M. Iwamoto,Adam M. Sonabend,Raul Rabadan +26 more
TL;DR: This study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor’s clonal evolution during treatment.
Journal ArticleDOI
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.
Journal ArticleDOI
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
Philip H. Gutin,Philip H. Gutin,Fabio M. Iwamoto,Kathryn Beal,Nimish Mohile,Sasan Karimi,Bob L. Hou,Stella C. Lymberis,Yoshiya Yamada,Jenghwa Chang,Lauren E. Abrey +10 more
TL;DR: Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
Journal ArticleDOI
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
John K. Park,Tiffany R. Hodges,Leopold Arko,Michael Shen,Donna Dello Iacono,Adrian McNabb,Nancy Bailey,Teri N. Kreisl,Fabio M. Iwamoto,Joohee Sul,Sungyoung Auh,Grace E. Park,Howard A. Fine,Peter McL. Black +13 more
TL;DR: A preoperative scale that identifies patients likely to have poor, intermediate, and good relative outcomes after surgical resection of a recurrent GBM tumor is devised and validated.
Journal ArticleDOI
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak,Lakshmi Nayak,Fabio M. Iwamoto,Ann S. LaCasce,Ann S. LaCasce,Srinivasan Mukundan,Srinivasan Mukundan,Margaretha G.M. Roemer,Bjoern Chapuy,Philippe Armand,Philippe Armand,Scott J. Rodig,Scott J. Rodig,Margaret A. Shipp,Margaret A. Shipp +14 more
TL;DR: The data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.